{
    "clinical_study": {
        "@rank": "114350", 
        "arm_group": [
            {
                "arm_group_label": "Vantobra; Treatment A", 
                "arm_group_type": "Experimental", 
                "description": "Vantobra, 170 mg tobramycin/1.7 mL nebulizer solution"
            }, 
            {
                "arm_group_label": "TOBI; Treatment B", 
                "arm_group_type": "Active Comparator", 
                "description": "TOBI, 300 mg tobramycin/5 mL nebulizer solution"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will investigate the bioequivalence and compare the safety profiles following\n      inhalation of Vantobra to TOBI nebulizer solution in healthy subjects.\n\n      Bioequivalence will be investigated based on the pharmacokinetic plasma profiles of Vantobra\n      nebulizer solution compared to TOBI nebulizer solution."
        }, 
        "brief_title": "Bioequivalence and Safety of Vantobra and TOBI in Healthy Subjects", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Cystic Fibrosis", 
        "condition_browse": {
            "mesh_term": [
                "Cystic Fibrosis", 
                "Fibrosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female healthy subjects of any ethnic origin\n\n          -  Aged between 18 and 50 years of age\n\n          -  Body weight of \u226550 kg and body mass index (BMI) between 18.5 and 29 kg/m2\n\n          -  FEV1 > 90% of predicted\n\n          -  Able to demonstrate correct inhaler use\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  History of clinically relevant allergies or idiosyncrasies to tobramycin or any other\n             inactive ingredient(s) of the IMP\n\n          -  Any history of drug hypersensitivity, asthma, urticaria, or other significant\n             allergic diathesis.\n\n          -  Any evidence of cardiovascular, pulmonary, renal, hepatic, gastrointestinal,\n             hematological, endocrinological, metabolic, neurological, psychiatric or other\n             diseases at screening\n\n          -  Surgery of the gastrointestinal or respiratory tract which might interfere with drug\n             absorption\n\n          -  History of malignancy within the past 5 years\n\n          -  History of orthostatic hypotension, faintings or blackouts\n\n          -  Acute or chronic viral, bacterial or fungal airway infections, including laryngeal\n             infections, mouth and throat infections, and hoarseness;\n\n          -  Other clinically relevant chronic or acute infectious illnesses\n\n          -  Clinical chemical, hematological or any other laboratory parameters clinically\n             relevant outside the normal range"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "72", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01953367", 
            "org_study_id": "12012.102"
        }, 
        "intervention": [
            {
                "arm_group_label": "Vantobra; Treatment A", 
                "description": "Inhalation", 
                "intervention_name": "Vantobra (tobramycin)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "TOBI; Treatment B", 
                "description": "Inhalation", 
                "intervention_name": "TOBI (tobramycin)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Tobramycin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Bioequivalence", 
            "AUC", 
            "Cmax"
        ], 
        "lastchanged_date": "April 24, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Gauting", 
                    "country": "Germany", 
                    "zip": "82131"
                }, 
                "name": "Inamed GmbH"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Bioequivalence and Safety Study of Vantobra and TOBI Nebulizer Solutions in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Inamed GmbH", 
            "last_name": "Wolgang Timmer, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Plasma AUClast of tobramycin", 
                "measure": "To investigate the bioequivalence (in terms of relative systemic bioavailability based on pharmacokinetic plasma profiles) of Vantobra 170 mg/1.7 mL nebulizer solution as compared to TOBI 300 mg/5 mL nebulizer solution in healthy subjects", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 7"
            }, 
            {
                "description": "Plasma Cmax of tobramycin", 
                "measure": "To investigate the bioequivalence (in terms of relative systemic bioavailability based on pharmacokinetic plasma profiles) of Vantobra 170 mg/1.7 mL nebulizer solution as compared to TOBI 300 mg/5 mL nebulizer solution in healthy subjects", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 7"
            }, 
            {
                "description": "tmax of tobramycin", 
                "measure": "To investigate the bioequivalence (in terms of relative systemic bioavailability based on pharmacokinetic plasma profiles) of Vantobra 170 mg/1.7 mL nebulizer solution as compared to TOBI 300 mg/5 mL nebulizer solution in healthy subjects", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 7"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01953367"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Adverse events", 
            "measure": "Number of Adverse Events during the trial period", 
            "safety_issue": "Yes", 
            "time_frame": "Adverse Events during the study period of max. 17 days"
        }, 
        "source": "Pari Pharma GmbH", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pari Pharma GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}